
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is viewed positively because its core immunology franchise remains exceptionally durable, with Skyrizi and Rinvoq delivering strong TRx growth and expected top-line beats that can offset Humira’s decline. The firm also benefits from a diversified, capital-efficient portfolio that was broadened by the 2020 Allergan deal and further strengthened in 2024 through Cerevel and ImmunoGen, while oncology and neuroscience provide additional upside. With no meaningful LOEs this decade, strong cash generation, a 3% dividend, and about $10-15bn of M&A capacity, its predictable double-digit EPS growth supports a premium fundamental outlook.
Bears say
AbbVie is facing a deteriorating fundamental profile as its base business growth weakens, operating margins come under pressure, and EPS growth slows, while valuation risk rises if the P/E multiple contracts to 13x. Competitive threats in immunology could erode Skyrizi and Rinvoq share, and disappointing clinical data, regulatory setbacks, or patent challenges would further undermine confidence in the portfolio. The 2020 Allergan deal and the 2024 Cerevel and ImmunoGen acquisitions broaden the platform, but integration risk, pricing فشار, and Aesthetics exposure at about 8% of FY 2025 sales leave the company vulnerable in a more defensive outlook.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AbbVie (ABBV) Forecast
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares